Deferiprone effectiveness in thalassemia major children with or without hepatitis B or C virus infection: a non-randomized study

  • Yovita Ananta Department of Child Health, Medical School, University of lndonesia, Cipto Mangunkusumo Hospital
  • Pustika Amalia Wahidiyat Department of Child Health, Medical School, University of lndonesia, Cipto Mangunkusumo Hospital
  • Hanifah Oswari Department of Child Health, Medical School, University of lndonesia, Cipto Mangunkusumo Hospital
Keywords: deferiprone, thalassemia, hepatitis B, hepatitis C, effectiveness

Abstract

Background A high incidence rate of hepatitis B or C virus
infection is found among thalassemia children in Indonesia. This
may influence deferiprone effectiveness.
Objective To determine the effectiveness of deferiprone in
thalassemia children with or without hepatitis B or C virus
infection.
Methods A non-randomized clinical study was performed at
Thalassemia Center Jakarta. Subjects were thalassemia children
with serum ferritin level > 1000 ng/mL who had hepatitis B or
C virus infection. A match control pair was recruited based on
similar duration of transfusion therapy, thalassemia type, and
initial serum ferritin level. All subjects received initial deferiprone
dose of 50 mg/kg/day for 3 months. Those whose ferritin decreased
2:: 10% continued to receive deferiprone of 50 mg/kg/day for the
following 3 months. Otherwise, deferiprone dose was adjusted
to 75 mg/kg/day.
Results Forty-eight subjects were recruited. After 3 months of
treatment, 16/24 subjects without and 6/24 subjects with hepatitis
B or C had their ferritin level decreased 2:: 10%. Mean ferritin
serum level of all subjects after 6 months was significantly reduced
from 4734 (SD 2116) to 3695 (SD 1709) ng/mL. Lower mean
deferiprone dose, lower mean post- study ferritin serum level and
higher mean percentage of ferritin serum level decrement were
found in subjects without hepatitis B or C infection than those
with infection.
Conclusions Deferiprone 50-7 5 mg/kg/day for 6 months is effective
in reducing serum ferritin level of thalassemia major children; it
is more effective in thalassemia children without hepatitis B or C
virus infection.

References

1. Rund D, Rachmilewitz E. ()-Thalassemia. N Engl J Med.
2005;353: 1135-46.
2. Data of Thalassemia Center Cipto Mangunkusumo Hospital,
Jakarta December 2008.
3. Permono B, Ugrasena IDG. Thalassemia. In: Permono B,
Sutaryo, Ugrasena IDG, Windiastuti E, Abdulsalam M,
editors. Buku ajar hematologi-onkologi anak (Textbook of
Pediatric Hematology-Oncology). Jakarta: Ikatan Dokter
Anak Indonesia, 2005; p. 64-84.
4. Cohen AR, Galanello R, Pennel DJ, Cunningham MJ,
Vichinsky E. Thalassemia. Hematology. 2004;1:14-32.
5. Thalassemia International Federation. Guidelines for the
clinical management of thalassemia. Athens: Thalassemia
International Federation; 2000.
6. Wahidiyat PA. Personal communication.Jakarta, 19 June 2008.
7. Anderson L, Holden S, Boris B, CardiovascularT2-star (T2*)
magnetic resonance for the early diagnosis of myocardial iron
overload. Eur Heart J. 2001 ;22 :2171-9.
8. Olivieri NF, Brittenham GM, Matsui D, Berkovitch M,
Blendis LM, Cameron RG, et al. Iron-chelation therapy with
oral deferiprone in patients with thalassemia major. N Engl]
Med. 1995;332:918-22.
9. Cohen AR, Galanello R, Piga A, DiPalma A, Vullo C,
Tricta F. Safety profile of the oral iron chelator deferiprone:
a multicentre study. Br] Haematol. 2000;108:305-12.
10. Olivieri NF, Brittenham GM, McLaren CE, Templeton
DM, Cameron RG, McClelland RA. Long-term safety and
effectiveness of iron-chelation therapy with deferiprone for
thalassemia major. N Engl J Med. 1998;339:417-23 .
11. Addis A, Loebstein R, Koren G, Einarson TR. Meta-analytic
review of the clinical effectiveness of oral deferiprone. Eur J
Clin Pharmacol. 1999;55:1-6.
12. Pootrakul P, Sirankapracha P, Sankote J, Kachintorn U,
Maungsub W, Sriphen K, et al. Clinical trial of deferiprone
iron chelation therapy in ()-thalassemia /hemoglobin E
patients in Thailand. Cr J Haematol. 2003;122:305-10.
13. Kowdley KV, Kaplan MM. Iron chelation therapy with
oral deferiprone: toxicity or lack of efficacy? N Engl J Med.
1998;339:468-9.
14. Mazza P, Amurri B, Lazzari G, Masi C, Palazzo G, Spartera
MA, et al. Oral iron chelating therapy. A single center interim
report on deferiprone (Ll) in thalassemia. Haemotologica.
1998;83:496-501.
15. Ced A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De
Sanctis V, et al. The safety and effectiveness of deferiprone in
a large-scale, 3-year study in Italian patients. Br J Haematol.
2002; 118:33 0-6.
16. Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C,
Cianciulli P. Deferiprone versus deferoxamine in patients
with thalassemia major: a randomized clinical trial. Blood
Cell Mol Dis. 2002;28: 196-208.
17. Chen AC, Peng CT, Wu SF, Wu KH, Chiang IP, Tsai CH.
Effect of deferiprone on liver iron overload and fibrosis
in hepatitis-C-virus-infected thalassemia. Hemoglobin.
112 • Paediatr lndones, Vol. 50, No. 2, March 2010
2006;30:209-14.
18. Olivieri NF, Brittenham GM. Iron-chelating therapy and the
treatment of thalassemia. Blood. 1997;89:739-61.
Published
2010-04-30
How to Cite
1.
Ananta Y, Wahidiyat P, Oswari H. Deferiprone effectiveness in thalassemia major children with or without hepatitis B or C virus infection: a non-randomized study. PI [Internet]. 30Apr.2010 [cited 27Jun.2022];50(2):105-2. Available from: https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/1215
Section
Articles
Received 2017-01-29
Accepted 2017-01-29
Published 2010-04-30